Intra-Cellular Therapies Inc. (NASDAQ: ITCI) stock closed at 57.73 per share at the end of the most recent trading day (a -1.32% change compared to the prior day closing price) with a volume of 873.27K shares and market capitalization of 5.45B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 383 people. Intra-Cellular Therapies Inc. CEO is Sharon Mates.

The one-year performance of Intra-Cellular Therapies Inc. stock is 53.62%, while year-to-date (YTD) performance is 10.3%. ITCI stock has a five-year performance of 440.04%. Its 52-week range is between 28.4 and 66, which gives ITCI stock a 52-week price range ratio of 78.01%

Intra-Cellular Therapies Inc. currently has a PE ratio of -16.20, a price-to-book (PB) ratio of 7.03, a price-to-sale (PS) ratio of 55.09, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -40.32%, a ROC of -41.78% and a ROE of -44.28%. The company’s profit margin is -%, its EBITDA margin is -301.90%, and its revenue ttm is $100.88 Million , which makes it $1.07 revenue per share.

Of the last four earnings reports from Intra-Cellular Therapies Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.93 for the next earnings report. Intra-Cellular Therapies Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Intra-Cellular Therapies Inc. is Strong Buy (1.5), with a target price of $66.75, which is +15.62% compared to the current price. The earnings rating for Intra-Cellular Therapies Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Intra-Cellular Therapies Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Intra-Cellular Therapies Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 16.56, ATR14 : 3.31, CCI20 : 112.37, Chaikin Money Flow : -0.04, MACD : 0.01, Money Flow Index : 61.79, ROC : 13.00, RSI : 56.45, STOCH (14,3) : 91.16, STOCH RSI : 0.80, UO : 64.98, Williams %R : -8.84), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Intra-Cellular Therapies Inc. in the last 12-months were: Christopher Alafi (Sold 75 000 shares of value $3 017 236 ), Joel S. Marcus (Option Excercise at a value of $0), Joel S. Marcus (Sold 20 000 shares of value $1 062 750 ), Lawrence J. Hineline (Option Excercise at a value of $2 941 950), Lawrence J. Hineline (Sold 205 082 shares of value $9 707 589 ), Mark Neumann (Option Excercise at a value of $1 099 210), Mark Neumann (Sold 131 883 shares of value $7 577 683 ), Michael I. Halstead (Option Excercise at a value of $2 897 493), Michael I. Halstead (Sold 207 641 shares of value $9 830 151 ), Rory B. Riggs (Option Excercise at a value of $0), Sharon Mates (Option Excercise at a value of $142 000), Sharon Mates (Sold 119 743 shares of value $5 250 841 ), Suresh K. Durgam (Option Excercise at a value of $0), Suresh K. Durgam (Sold 25 307 shares of value $1 224 844 )